112 results about "Postmenopausal women" patented technology

The subject invention provides methods for evaluating women in designing appropriate menopausal and postmenopausal therapies to match the particular needs of the individual. In one embodiment, the subject invention provides methods for evaluating particular factors in menopausal and postmenopausal women that are then taken into account in identifying a therapy program to promote good health and reduce the risk of any adverse health effects as a result of the therapy, specifically the role of hormone induced / associated breast cancer. More specifically, the subject invention includes methods for evaluating menopausal and postmenopausal women to determine whether hormone replacement therapy is appropriate in this regard, and if so, the specifics of how that therapy is to be administered. The subject invention, by incorporating various factors into a comprehensive, function breast hormone profile, allows for the identification of untreated women with estrogen-related metabolic abnormalities that may increase the risk of breast cancer. The subject invention determines specific therapies to correct and / or inhibit the aberrant biosynthetic pathways, and thus, the risk of cancer.

Methods for commercial production of transdermal formulations comprising a hormone compound are provided. In particular, methods for commercial scale production under an inert atmosphere of a transdermal formulation comprising a therapeutically effective amount of a hormone, preferably a testosterone compound, useful for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women are provided.

The invention relates to novel inulin products and compositions thereof, to their manufacture, to their use for modifying and modulating the bacterial flora and the fermentation pattern of inulin in the large intestine of humans, mammals or other vertebrates, to their use for providing improved inulin-associated nutritional effects / benefits, as well as to their use for the manufacture of consumer products and compositions for providing said effects / benefits in healthy, disfunctioned and diseased humans, mammals and other vertebrates. The novel inulin products consist of a particular mixture of an easily fermentable inulin (EFI) component and a hardly fermentable inulin (HFI) component. The nutritional effects / benefits include dietary fibre effects, improved mineral absorption, particularly calcium and magnesium, bone mineral density increase, reduction of bone mineral density loss, modulation of lipid metabolism, stimulation of the immune system, and anti-cancer effects. The novel inulin products are particularly suitable for the manufacture of a composition or a medicament for preventing, for postponing and / or for treating osteoporosis in humans, particularly in post-menopausal women and elderly people.

This invention is directed to a multi-vitamin and mineral supplement tailored to men and post-menopausal women, pre-menopausal women, and athletes which supplies the right amount of the right micronutrients at the right time to assure adequate intake of micronutrients needed for disease prevention and protection against nutritional losses and deficiencies due to lifestyle factors and common inadequate dietary patterns. The multi-vitamin and mineral supplement is comprised of vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, niacinamide, vitamin B6, vitamin B12, biotin, pantothenic acid, iron, iodine, magnesium, zinc, selenium, copper, chromium, potassium, choline, lycopene, and co-enzyme Q-10.

The invention relates to a health-care food, and specifically relates to corn nutrition powder which is composed of corn powder, lobed kudzuvine root, and lotus root starch. According to a total weight of the corn nutrition powder, the powder comprises 97-98% of corn, 1-1.5% of lobed kudzuvine root, and 0.8-1.5% of lotus root starch. With the corn nutrition powder, diseases such as hyperlipemia, hypertension, myocardial infarction, arteriosclerosis, and the like can be prevented. With the unique formula, the product also has a liver protecting and kidney protecting function, and a hangover-relieving and detoxifying special function. When the powder is eaten for a long time, diseases such as senile dementia and poor memory can be prevented. Kudzuvine root flavone has an anticancer function. When the powder is taken for a long time, breast enhancing and beautifying functions can be provided for women. The corn nutrition powder has substantial beautifying and health-care functions for middle-aged women and postmenopausal women.

Compositions and methods for the treatment of osteoporosis and / or inflammatory joint disease are provided herein. The compositions contain a folate, such as a reduced folate, and folic acid. The folate is preferably 5-methyltetrahydrofolate, and most preferably 5-methyl-(6S)-tetrahydrofolic acid. The folate and folic acid can be given in the same dosage unit or separate dosage units, and more than one dosage unit can be given per dose. The compositions may also contain one or more vitamins and minerals selected from vitamin B12, vitamin B6, vitamin D3, calcium, magnesium, and polyunsaturated fatty acids (PUFAs). These ingredients are optional, but preferable (especially the vitamins and minerals). The compositions may further contain one or more additional ingredients such as vitamins, minerals, and laxatives. The compositions are useful in the treatment of all forms of osteoporosis, including primary osteoporosis and secondary osteoporosis, and / or inflammatory joint diseases, especially in patients having a folic acid metabolism deficiency. The compositions are particularly useful in the treatment of inflammatory joint diseases, with complications that include bone loss, fracture, and osteoporosis. In addition, the compositions are beneficial for the prevention of osteoporosis in subjects who do not yet have the disease, but who are at risk for getting osteoporosis, such as post-menopausal women, subjects with osteopenia (mid thinning of the bone mass), subjects with an inflammatory joint disease, or people who are over the age of 70.

The invention discloses antibodies that bind high specificity to human RANKL (Receptor Activator for Nuclear Factor kappa B Ligand), wherein, the antibodies are used for the treatment of bone erosion caused by astogeny, hormonotherapy, postmenopausal osteoporosis, bone metastasis, and inflammation. The invention also discloses DNA sequences and supposed amino acid sequences of the antibodies.

The invention relates to a compound protein powder for preventing postmenopausal women from osteoporosis. The components and weight percentage thereof are: 55 percent to 80 percent of soybean protein powder; 15 percent to 35 percent of whey powder, 0.2 percent to 0.8 percent of soybean isoflavone, 1 percent to 5 percent of oligosaccharide, 1.2 percent to 2.4 percent of calcium lactate, 0.5 percent to 1 percent of stabilizer and 0.5 percent to 1.5 percent of lecithin. The product of the invention is safe and reliable to eat, which has good effect, innocuity, no side effects and dependence. Furthermore, the invention can protect the health of middle-aged women by eating often, especially for improving the healthy problems caused by lacking of estrogen, so as to improve the life quality and living quality of women. Therefore, the invention can be taken as a protein complementary product to be eaten frequently by women.

The present invention provides methods for boosting mucosal immunity in the female reproductive tract of pre- and post-menopausal women using a TGF-beta inhibitor, a Selective Estrogen Receptor Modulator, and / or a recombinant commensal bacterium that expresses endogenous microbicides into the intestinal tract or reproductive tract of a subject. It also provides methods for boosting innate and adaptive immunity by providing a glucocorticoid. Methods for preventing sexually transmitted infections including HIV infection are also provided.

The invention relates to novel inulin products and compositions thereof, to their manufacture, to their use for modifying and modulating the bacterial flora and the fermentation pattern of inulin in the large intestine of humans, mammals or other vertebrates, to their use for providing improved inulin-associated nutritional effects / benefits, as well as to their use for the manufacture of consumer products and compositions for providing said effects / benefits in healthy, disfunctioned and diseased humans, mammals and other vertebrates.The novel inulin products consist of a particular mixture of an easily fermentable inulin (EFI) component and a hardly fermentable inulin (HFI) component.The nutritional effects / benefits include dietary fiber effects, improved mineral absorption, particularly calcium and magnesium, bone mineral density increase, reduction of bone mineral density loss, modulation of lipid metabolism, stimulation of the immune system, and anti-cancer effects. The novel inulin products are particularly suitable for the manufacture of a composition or a medicament for preventing, for postponing and / or for treating osteoporosis in humans, particularly in post-menopausal women and elderly people.

The present invention relates to pharmaceutically acceptable complex formulae comprising complexes of Fulvestrant, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulae of the present invention have improved physicochemical properties which makes the compound orally available and makes oral administration of the compound possible in the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.

The invention relates to a new preparation method of strontium ranelate heptahydrate. The products produced by the method have water content of 19.0 per cent to 20.4 per cent and the relevant substances are lower than 0.5 per cent. The strontium ranelate heptahydrate produced by the method is stable under room temperature, has little water content differences between batches and is kept for a long time under natural environment with unchangeable moisture, content and relevant substances. The method is characterized in that: (1) the reflux of the 2-[N, N- 2(carboxymethyl)amino]-3-cyano-group-4-thiopheneacetic-5-carboxylic acid tetra ester (b) is carried out in the proper sodium hydroxide aqueous solution of alcohol for 5h to 6h and the pH value is kept over 10 during hydrolysis; (2) the ethanol of 20 per cent to 60 per cent is added and then the strontium chloride aqueous solution with 2times to 2.5times molal weight is directly added, precipitates the crystal, is filtered and dried; (3) water is added to carry out the reflux and the little salt packed in the crude product is removed, and the product is collected through heat filtration. The invention discloses the drug combination containing the strontium ranelate heptahydrate which is used for the treatment of osteoporosis of women after menopause.

The invention discloses a preparation method of a dispersible tablet containing a letrozole-hdrophilic material blend. The dispersible tablet contains a letrozole-hydrophilic material blend and other pharmaceutically acceptable excipients. A wet granulation and tablet compression method is employed for the preparation of the dispersible tablet. The dispersible tablet has good dispersion uniformity, and can effectively improve the dissolution rate of a letrozole solid preparation, improve the compliance for patient administration and bioavailability of the drug. The dispersible tablet can be used for the treatment of breast cancer in postmenopausal women; and the method is simple and applicable to industrialized production.

The invention provides a vitamin K2 compound for preventing and treating arthritis, and belongs to the field of medicine or health-care food formulae. Per 1000g of the compound comprises 0.05-0.25g of vitamin K2, 0.005-0.01g of vitamin D, 500-750g of glucosamine and 499.945-249.740g of solid or liquid matrix. The compound which is mechanically stirred and uniformly mixed under a normal temperature or heating condition is prepared to soft capsules, hard capsules or troches. The medicine or health-care food formed by the formula has remarkable preventing and treating effects on common osteoarthritis of the middle aged or the aged people, especially postmenopausal women.

A pharmaceutical composition comprises at least one estrogenic compound, the composition being adapted for application in a unit dose amount to a vulvovaginal surface and having at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface, wherein the at least one estrogenic compound is present in an amount of about 5 to about 1000 μg estradiol equivalent per unit dose of the composition, and upon application of the composition to the vulvovaginal surface the at least one estrogenic compound is released over a period of about 3 hours to about 30 days. The composition is useful for vulvovaginal administration to treat atrophic vaginitis or a disorder associated therewith, for example in a menopausal or postmenopausal woman. A method for treating a hypoestrogenism-related condition of the urogenital system of a female patient comprises intravaginal administration of at least one estrogenic compound according to a treatment regimen wherein a series of compositions releasing a progressively increasing daily amount of the at least one estrogenic compound is administered over a period of at least about 1 month.

The invention provides a method for purifying gonadotropins extracted from urine of postmenopausal women. Compared with the extraction separation of the existing gonadotropins, the method of the invention has the following advantage: the gonadotropins which are obtained by the method of the invention and take FSH and LH as the main components have higher titer which is more than 150iu / mg) and higher yield which is more than 75%.

The present invention is directed to a method of treating, preventing, or reducing the risk of bone deterioration or osteoporosis in a peri- or post-menopausal female subject. The method involves selecting a peri- or post-menopausal female subject in need of treating, preventing, or reducing the risk of bone deterioration or osteoporosis and administering hepcidin to the selected subject under conditions effective to treat, prevent, or reduce the risk of bone deterioration or osteoporosis.

Osteoporosis is one of the major problems in our aging society. Osteoporosis results in bone fracture in older members of the population, especially in post-menopausal women. In traditional medicine, there are many natural crude drugs that have the potential for use to treat bone diseases. So far, there is no report in literature on anti-osteoporosis (bone forming) activity of Butea species. It was thought to study the anti-osteoporotic activity of this plant. Thus, the present invention provides a pharmaceutical composition from the extracts of Butea monosperma for prevention or treatment of bone disorders, process of preparation and use thereof.

Letrozole cutaneous penetration patch and its preparation method, it involves a cutaneous penetration patch and the patch preparation methods. The invention solves problems of the present Letrozole available dosage form drugs in the treatment of postmenopausal women with advanced aspects in short effective time, frequent administration, a more dverse reactions. It consists of matrix layer, back lining and protective film. The matrix layer of letrozole cutaneous penetration patch includes letrozole, adhesives and organic solvents. Their preparation methods: (a) spraid the mixture of letrozole, adhesives and organic solvents evenly on the back lining; (b) after they are dried, cover the protective membrane on the other surface of the patch matrix layer, then the letrozole cutaneous penetration patch is obtained. The patches matrix layer of the invention has good compatibility and adhesiveness with skin, good stability. The invention of the patches maintains constant speed, uniform release, obvious treatment results and long effective time, long recurrence interval, low recurrence rate. Preparation of the present invention patch method is simple and easy to operate.

The invention is to methods for screening women for breast cancer and precancer by determining a level of an estrogen-related marker. The invention further provides methods of treating such patients identified as having one or more abnormal ductal epithelial cells and an estrogen-related marker. The invention provides methods for screening patient for hormone replacement therapy (HRT), and of monitoring such patients once they begin HRT. The invention provides methods of treating peri-, menopausal or postmenopausal women for both cancer risk reduction and menopausal symptoms (or other conditions related to lowered systemic estrogen levels). The invention also provides kits for the screening, monitoring, and treating methods described.

The invention belongs to medical technology, in particular to a dispersible tablet form of anastrozole. Through a large number of clinical investigations, we have overcome the technical prejudice that anastrozole does not need to be developed into dispersible tablets in the prior art, and obtained the present invention. Clinical experiments have confirmed that the adverse reactions of the present invention are significantly reduced, and the compliance of medication is significantly improved. Obtained unexpected clinical efficacy. It has the characteristics of low production cost, stable preparation, fast absorption and high bioavailability. The invention is suitable for treating advanced breast cancer of postmenopausal women, and provides a good therapeutic drug dosage form for breast cancer patients.

The invention relates to fatty acid raloxifene derivatives; compositions comprising an effective amount of a fatty acid raloxifene derivative; and methods for treating osteoporosis or preventing invasive breast cancer in postmenopausal women comprising the administration of an effective amount of a fatty acid raloxifene derivative.

The present invention provides for the administration of aryl-substituted 1,1-diphosphonate compounds to increase the dermal collagen content of skin and effect improvement in photoaged skin, chronologically aged skin and in skin of postmenopusal women and patients suffering from osteoporosis.

The invention relates to the technical field of preparation of compounds for promoting bone health, and provides a preparation method of a sea cucumber oyster glycopeptide calcium complex. The methodcomprises the following steps: subjecting sea cucumbers and oyster meat to enzymolysis so as to obtain a sea cucumber oyster glycopeptide solution, subjecting the sea cucumber oyster glycopeptide solution to enzymolysis, then preparing calcium acetate by using the oyster shells, and chelating the calcium acetate with sea cucumber oyster glycopeptides so as to obtain the sea cucumber oyster glycopeptide calcium complex. The invention also provides a preparation method of a sea cucumber oyster glycopeptide calcium complex compound, and the method compounds the sea cucumber oyster glycopeptide calcium complex with glucosamine, medicinal and edible extract and a calcium absorption enhancer so as to obtain the sea cucumber oyster glycopeptide calcium complex compound. Thereby, the sea cucumberoyster glycopeptide calcium complex compound provided by the invention can be used as a natural health product for promoting bone health, and can improve the symptoms of osteoporosis and osteoarthritis which are prevalent among middle-aged or postmenopausal women.

The invention discloses an application of miR-6802-3p to early diagnosis of postmenopausal osteoporosis. MiRNA with differential expression between a postmenopausal osteoporosis patient and a normal control is screened out by sequencing, then large sample QPCR experiments prove that content of miR-6802-3p in blood of the postmenopausal osteoporosis patient is substantially up-regulated definitely,so that miR-6802-3p can serve as a molecular marker for diagnosing postmenopausal osteoporosis to be used for developing products for diagnosing postmenopausal osteoporosis.

A process for separating soybean hypocoty includes scalding soybean seeds by hot water for instantaneously stimulating them, soaking in cold water for germinating, peeling, growing seed lobes, separating hypocoty from seed lobes, low-temp drying, and extracting soybean isoflavone, which can be used for preventing and treating the menopathy of menopausal woman, vaginitis, cardiovascular disease and cancer.